Ki67 increase after core needle biopsy associated with worse disease outcome in HER2-negative breast cancer patients
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ki67 increase after core needle biopsy associated with worse disease outcome in HER2-negative breast cancer patients
Authors
Keywords
-
Journal
Scientific Reports
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-02-14
DOI
10.1038/s41598-022-25206-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer
- (2019) Mustapha Abubakar et al. MODERN PATHOLOGY
- Can breast cancer patients with HER2 dual-equivocal tumours be managed as HER2-negative disease?
- (2018) Yiwei Tong et al. EUROPEAN JOURNAL OF CANCER
- Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis
- (2017) Lun Li et al. Future Oncology
- Differences in Ki67 expressions between pre- and post-neoadjuvant chemotherapy specimens might predict early recurrence of breast cancer
- (2017) Emi Tokuda et al. HUMAN PATHOLOGY
- Comparison of Core Needle Biopsy and Surgical Specimens in Determining Intrinsic Biological Subtypes of Breast Cancer with Immunohistochemistry
- (2017) Kiho You et al. Journal of Breast Cancer
- Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results
- (2017) Oleg Gluz et al. JNCI-Journal of the National Cancer Institute
- Comparison of Core Needle Biopsy and Excision Specimens for the Accurate Evaluation of Breast Cancer Molecular Markers: a Report of 1003 Cases
- (2017) Jie Chen et al. PATHOLOGY & ONCOLOGY RESEARCH
- Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results
- (2017) Oleg Gluz et al. JNCI-Journal of the National Cancer Institute
- The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis
- (2016) Yan Mao et al. PLoS One
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) E. Senkus et al. ANNALS OF ONCOLOGY
- Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients
- (2015) Xiaosong Chen et al. BMC CANCER
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
- (2014) S. Loi et al. ANNALS OF ONCOLOGY
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
- (2014) Sylvia Adams et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials
- (2013) S. Gandini et al. ANNALS OF ONCOLOGY
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
- (2013) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer
- (2013) Xiaosong Chen et al. BMC CANCER
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Accuracy of Estrogen and Progesterone Receptor Assessment in Core Needle Biopsy Specimens of Breast Cancer
- (2013) Ramesh Omranipour et al. Iranian Red Crescent Medical Journal
- Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis
- (2012) Xiaosong Chen et al. BREAST CANCER RESEARCH AND TREATMENT
- Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial
- (2012) Bernardo Bonanni et al. JOURNAL OF CLINICAL ONCOLOGY
- Does Breast Tumor Heterogeneity Necessitate Further Immunohistochemical Staining on Surgical Specimens?
- (2012) Lauren T. Greer et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients
- (2008) R. Stuart-Harris et al. BREAST
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started